Lambrolizumab causes regression of advanced melanoma

This study investigated whether the PD-1 antibody lambrolizumab improves the condition of patients with advanced melanoma.

The programmed death 1 (PD-1) receptor is a structure normally found on cells of the immune system, and when activated inhibits their activity. Some cancer cells can activate the PD-1 receptor and this helps them avoid the immune response. Lambrolizumab is a drug that targets the PD-1 receptor, and it is thought that this could allow the immune system to detect and destroy cancer cells.

Researchers investigated the effects of lambrolizumab in 135 advanced melanoma patients. All patients were diagnosed with an unresectable (inoperable) melanoma. One of three doses of lambrolizumab (10 mg/kg every 2 weeks, 10 mg/kg every 3 weeks, or 2 mg/kg every 3 weeks) were prescribed to patients.

The average confirmed response rate was 38% (a confirmed response is defined as a proven regression in tumor size shown in multiple imaging scans at different times). The strongest effect (52%) was seen in the group treated with 10 mg/kg every 2 weeks. Lambrolizumab was effective regardless of whether or not patients were previously treated with other immune targeting drugs such as ipilimumab (yervoy).

Lambrolizumab is effective at preventing tumor progression in patients with advanced melanomas.

This study was sponsored by Merck, Sharpe and Dohme, a pharmaceutical group that produces the drug lambrolizumab.

Consult with your physician about lambrolizumab in the treatment of advanced melanomas.